68 related articles for article (PubMed ID: 15557791)
41. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
44. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
45. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
Fischer-Colbrie J; Witt A; Heinzl H; Speiser P; Czerwenka K; Sevelda P; Zeillinger R
Anticancer Res; 1997; 17(1B):613-9. PubMed ID: 9066588
[TBL] [Abstract][Full Text] [Related]
46. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
47. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
Köbel M; Turbin D; Kalloger SE; Gao D; Huntsman DG; Gilks CB
Int J Gynecol Pathol; 2011 Jul; 30(4):366-71. PubMed ID: 21623201
[TBL] [Abstract][Full Text] [Related]
48. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas.
Dobashi Y; Jiang SX; Shoji M; Morinaga S; Kameya T
J Pathol; 2003 Feb; 199(2):208-20. PubMed ID: 12533834
[TBL] [Abstract][Full Text] [Related]
49. Frequent overexpression of p53 in dysgerminoma of the ovary.
Dietl J; Horny HP; Kaiserling E
Gynecol Obstet Invest; 1994; 37(2):141-2. PubMed ID: 8150371
[TBL] [Abstract][Full Text] [Related]
50. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.
Salani R; Davidson B; Fiegl M; Marth C; Müller-Holzner E; Gastl G; Huang HY; Hsiao JC; Lin HS; Wang TL; Lin BL; Shih IeM
Clin Cancer Res; 2007 Oct; 13(19):5805-9. PubMed ID: 17908972
[TBL] [Abstract][Full Text] [Related]
51. Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle.
Pang W; Li Y; Guo W; Shen H
Am J Transl Res; 2020; 12(9):5170-5187. PubMed ID: 33042412
[TBL] [Abstract][Full Text] [Related]
52. Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.
Castro MP; Whitcomb BP; Zajchowski DA; Coleman RL
Gynecol Oncol Res Pract; 2015; 2():4. PubMed ID: 27231564
[TBL] [Abstract][Full Text] [Related]
53. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Kobayashi H; Sugimoto H; Onishi S; Nakano K
Oncol Lett; 2015 Aug; 10(2):612-618. PubMed ID: 26622542
[TBL] [Abstract][Full Text] [Related]
54. Development of a syngeneic mouse model of epithelial ovarian cancer.
Quinn BA; Xiao F; Bickel L; Martin L; Hua X; Klein-Szanto A; Connolly DC
J Ovarian Res; 2010 Oct; 3():24. PubMed ID: 20958993
[TBL] [Abstract][Full Text] [Related]
55. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes.
D'Andrilli G; Giordano A; Bovicelli A
Open Clin Cancer J; 2008 Feb; 2():7-12. PubMed ID: 18665245
[TBL] [Abstract][Full Text] [Related]
56. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary.
Tsuda H; Bandera CA; Birrer MJ; Hashiguchi Y; Berkowitz RS; Mok SC
Oncology; 2004; 67(3-4):291-9. PubMed ID: 15557791
[TBL] [Abstract][Full Text] [Related]
57. Cyclin E mRNA overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation.
Sawasaki T; Shigemasa K; Shiroyama Y; Kusuda T; Fujii T; Parmley TH; O'Brien TJ; Ohama K
J Soc Gynecol Investig; 2001; 8(3):179-85. PubMed ID: 11390254
[TBL] [Abstract][Full Text] [Related]
58. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
59. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
60. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
